- Home
- CNOB vs ATAI Comparison
CNOB vs ATAI Comparison
Compare CNOB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | ATAI |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | 54 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNOB | ATAI |
|---|---|---|
| Price | $25.86 | $3.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $30.33 | $15.57 |
| AVG Volume (30 Days) | 298.5K | ★ 4.5M |
| Earning Date | 04-23-2026 | 03-06-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | $42.85 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | $17.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.61 | $1.15 |
| 52 Week High | $29.28 | $6.73 |
Technical Indicators
Market Signals| Indicator | CNOB | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 40.88 |
| Support Level | $25.88 | $3.06 |
| Resistance Level | $26.26 | $4.30 |
| Average True Range (ATR) | 0.74 | 0.21 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 54.71 | 6.14 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.